Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants

Brazil currently has a 10-valent pneumococcal conjugate vaccine (PCV10) pediatric national immunization program (NIP). However, in recent years, there has been significant progressive increases in pneumococcal disease attributed to serotypes 3, 6A, and 19A, which are covered by the 13-valent PCV (PC...

Descrición completa

Detalles Bibliográficos

Principais autores:	Johnna Perdrizet, Carlos Felipe S. Santana, Thais Senna, Rodrigo Fernandes Alexandre, Rodrigo Sini de Almeida, Julia Spinardi, Matt Wasserman
Formato:	Artigo
Idioma:	Inglês
Publicado:	Taylor & Francis Group 2021-04-01
Series:	Human Vaccines & Immunotherapeutics
Assuntos:	brazil cost-effectiveness budget impact economic evaluation cost-utility analysis pcv pneumococcal vaccine streptococcus pneumoniae national immunization program
Acceso en liña:	http://dx.doi.org/10.1080/21645515.2020.1809266
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!